<DOC>
	<DOCNO>NCT01901172</DOCNO>
	<brief_summary>This multicenter , open-label study evaluate effect posaconazole pharmacokinetics RO5503781 , relative bioavailability two new RO5503781 formulation , effect food pharmacokinetics RO5503781 patient solid tumor .</brief_summary>
	<brief_title>A Study Drug-Drug Interaction RO5503781 Posaconazole , Relative Bioavailability New Formulations RO5503781 Food-Effect Pharmacokinetics RO5503781 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm advanced malignancy , except form leukemia lymphoma , standard curative palliative measure exist , longer effective , acceptable patient Measureable evaluable disease ( RECIST criterion version 1.1 solid tumor prior administration study drug Life expectancy &gt; /= 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Female patient childbearing potential male patient surgically sterile must willing use effective method contraception define protocol treatment period 10 day last dose RO5503781 . There limitation additional , allowable type amount prior antitumor therapy . Acute toxicities prior antitumor therapy , surgery , radiotherapy must resolve NCICTCAE version 4.03 Grade &lt; /= 1 . The last dose prior therapy must &gt; /= 21 day prior first administration study drug RO5503781 ( &gt; /= 5 x terminal halflife therapy ) . Adequate bone marrow , hepatic renal function Patients stable CNS metastasis ( therapy require therapy , steroid , change screen CT MRI asymptomatic ) , eligible Any form leukemia except Stage 0 1 chronic lymphocytic leukemia ( CLL ) require treatment addition underlie malignancy Hormonal therapy within 2 week prior first dose study medication . Patients prostate cancer surgically castrate remain GnRH analogue . Patients use investigational agent receive investigational drug &lt; /= 4 week prior study treatment start . Preexisting GI disorder may interfere proper absorption drug ( ) , per investigator discretion . History allergic reaction attribute component formulated product History seizure disorder unstable CNS metastases Any severe and/or uncontrolled medical condition condition could affect participation study Patients must receive CYP2C8 inhibitor , substrates inducer , strong CYP 3A4 inducer moderate/strong CYP3A4 inhibitor list protocol study . Substrates , inducer , inhibitor list protocol must discontinue 7 14 day prior start study medication . Evidence electrolyte imbalance ( treatment correction electrolyte imbalance permit screen meet eligibility ) Pregnant breast feed woman HIVpositive patient currently receive combination antiretroviral therapy Patients know coagulopathy , platelet disorder history nondrug induce thrombocytopenia . Patients receive oral parenteral anticoagulants/antiplatelet agent ( e.g. , chronic daily treatment aspirin ( &gt; 325 mg/day ) , clopidogrel , low molecular weight heparin , subcutaneous anticoagulant prophylaxis ) . A washout period least 7 day prior start study require . Patients may receive anticoagulant flush maintenance indwell catheter . Patients refuse potentially receive blood product and/or hypersensitivity blood product Part 1 : Hypersensitivity posaconazole , ingredient , azole antifungal Part 1 Part 3 : Patients tolerate highfat and/or full meal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>